Illinois Breast and Cervical Cancer Program - Eligibility/How to Apply - breast cancer free treatment illinois

Category

breast cancer free treatment illinois - Policy Initiatives & Advocacy


The Illinois Breast and Cervical Cancer Program offers free mammograms, breast exams, pelvic exams and Pap tests to eligible women. Even if a woman has already been diagnosed with cancer, she may receive free treatment if she qualifies. The program has been providing breast and cervical cancer screenings to the women of Illinois since 1995. Cancer is the second most common cause of death in Illinois and the United States, and the leading cause of death for Illinois citizens aged 45-64. During 2009, the underlying cause of death for 24,182 Illinoisans was cancer. In the same year, new invasive cancer cases totaling 64,135 were diagnosed among Illinois residents. Cancer affects all.

Eligibility/How to Apply. Am I eligible to receive a free screening through the Illinois Breast and Cervical Cancer Program? You may be able to receive free services if you are a woman: or if you are a woman diagnosed with breast and/or cervical cancer who may qualify for treatment. Cancer Treatment Centers of America ® (CTCA) provides cancer care at three area locations. CTCA ® Chicago is a comprehensive cancer treatment hospital located in Zion, Illinois, midway between Chicago and Milwaukee. At our Chicago hospital, experienced doctors, Magnet ®-recognized nurses and other clinicians work together in one location, providing integrative cancer treatment tailored to Location: 2520 Elisha Ave, Zion, 60099, IL.

The American Cancer Society has programs and services to help you manage cancer treatment and recovery and find the emotional support you need. And best of all, our help is free. Find programs and services in Illinois. Breast cancer occurs in both men and women, although male breast cancer is rare. Estimated new cases of breast cancer in the United States in 2016: 249,260 (female); 2,600 (male) In the United States, breast cancer is the most common non-skin cancer and the second leading cause of .